InflaRx N : 11-2023-InflaRx Reports Third Quarter 2023 Finan

Jena, Germany, November 1, 2023 - InflaRx N.V. , a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today financial results...

Related Keywords

United States , Germany , German , Thomas Taapken , German Ministry Of Education , Development Expenses , Development Of Vilobelimab , Drug Administration , European Medicines Agency , Inflarx Stops Development Of Vilobelimab , European Union , German Ministry Of Health , Recent Highlights , Business Update , Topline Results , Single Ascending Dose , Phasei Trial Support Best In Class Potential , Pyoderma Gangrenosum , Authorization Application , Critically Ill , European Committee , Medicinal Products , Human Use , Emergency Use Authorization , Cutaneous Squamous Cell Carcinoma , German Ministry , Chief Financial Officer , Marketing Expenses , Administrative Expenses , Cash Used , Markets ,